China Grand Enterprises, Inc. Ranks Fourth among China’s Top 100 Pharmaceutical Industrial Enterprises for 2025
On July 12, the 2026 (43rd) National Medicinal Industry Information Annual Conference was held in Beijing. At the conference, the China National Pharmaceutical Industry Information Center released the 2025 Top 100 Pharmaceutical Industrial Enterprises in China by Main Business Revenue. China Grand Enterprises, Inc. was once again included in the ranking, ranking fourth.
On July 12, the 2026 (43rd) National Medicinal Industry Information Annual Conference was held in Beijing. At the conference, the China National Pharmaceutical Industry Information Center released the 2025 Top 100 Pharmaceutical Industrial Enterprises in China by Main Business Revenue. China Grand Enterprises, Inc. was once again included in the ranking, ranking fourth.
CGE’s pharmaceutical and healthcare sector (hereinafter referred to as “CGE Healthcare”) is composed of four major healthcare groups—Huadong Medicine, Grand Pharmaceutical, Grand Life Sciences, and Leiyunshang Pharmaceutical—forming a comprehensive healthcare group with broad therapeutic coverage, a rich and diversified product portfolio, and leading technological capabilities. The sector provides more than 1,000 healthcare-related products, including pharmaceuticals, medical devices, active pharmaceutical ingredients (APIs), chemical intermediates, and science-based health products. CGE Healthcare has established a globalized R&D and manufacturing network, with a strategic focus on frontier areas such as innovative medicines, nuclear medicine diagnosis and treatment, advanced formulations, mRNA therapeutics, high-end medical devices, and full-spectrum health aesthetics. Multiple R&D technology platforms and R&D centers have been deployed worldwide. In 2025, the results of optimizing the Company’s product portfolio continued to manifest, while the R&D and commercialization of innovative products with strong technological barriers continued to accelerate. Multiple innovative products received marketing approval, and the Company achieved a number of milestone advances in R&D innovation and international expansion.
Looking ahead, Grand Health will uphold its business philosophy of “research-based, patient-centered, and market-oriented,” consistently placing innovation at the core of its strategy. Through multiple approaches, including the development of proprietary R&D platforms, industry-academia-research collaboration, and international cooperation, the Company will continue to launch new products and provide a solid foundation for sustainable and high-quality development.